Boston Scientific (BSX) said it now estimates net sales growth for the full year 2026 to be approximately 7.0 to 8.5 percent on a reported basis and 6.5 to 8.0 percent on an organic basis. The company now estimates adjusted EPS, excluding certain items, of $3.34 to $3.41. The company previously estimated net sales growth to be approximately 10.5 to 11.5 percent on a reported basis and 10.0 to 11.0 percent on an organic basis, and adjusted EPS, excluding items, of $3.43 to $3.49.
The company estimates net sales growth for the second quarter of 2026 to be approximately 5.5 to 7.5 percent on a reported basis and 5.0 to 7.0 percent on an organic basis. The company estimates adjusted EPS, excluding certain items, of $0.82 to $0.84.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.